Cargando…
Evaluation of the abuse potential of pitolisant, a selective H(3)-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy
OBJECTIVES: To evaluate the human abuse potential of pitolisant, a selective histamine 3 (H(3))-receptor antagonist/inverse agonist recently approved by the US Food and Drug Administration for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. METHODS: Nondependent, rec...
Autores principales: | Setnik, Beatrice, McDonnell, Michael, Mills, Catherine, Scart-Grès, Catherine, Robert, Philippe, Dayno, Jeffrey M, Schwartz, Jean-Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157189/ https://www.ncbi.nlm.nih.gov/pubmed/31626696 http://dx.doi.org/10.1093/sleep/zsz252 |
Ejemplares similares
-
Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study
por: Dauvilliers, Yves, et al.
Publicado: (2019) -
Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials
por: Meskill, Gerard J., et al.
Publicado: (2021) -
Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials
por: Watson, Nathaniel F., et al.
Publicado: (2021) -
Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility
por: Guevarra, Jay T, et al.
Publicado: (2020) -
Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
por: van der Hoeven, Adrienne Elisabeth, et al.
Publicado: (2022)